Head and Neck Cancer
Conditions
Keywords
TCR-T therapy
Brief summary
This study will obtain tumor samples from patients with head and neck cancers and aims to develop personalized TCR-T therapy for head and neck cancer by determining the reactive TCR clone sequences in head and neck cancer.
Interventions
OTHERNo intervention
This is a preclinical study. No intervention will be performed.
Sponsors
Eye & ENT Hospital of Fudan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Gender is not limited, age 18-75 years old; 2. Estimated survival is greater than 3 months; 3. Newly diagnosed patients with head and neck cancer without any treatment, or patients with refractory recurrent advanced head and neck cancer for which there is no available effective treatment; 4. Patients with head and neck cancer whose tumor tissue can be surgically harvested; 5. Volunteer to join the study and sign the informed consent.
Exclusion criteria
1. Infected or had been infected with COVID-19; 2. Active hepatitis B or C virus, HIV infection, or other uncured active infected persons; 3. Patients with head and neck cancer who had received the following treatments: The patient had a history of using PD-1 and other immune checkpoint inhibitors 8 weeks before surgery; History of chemotherapy drug use 8 weeks before surgery; A history of hormone drug use within 4 weeks before surgery; 4. Other situations that are not appropriate to be included in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical prognosis | 5 year postsurgery | Observation of the clinical prognosis including overall survival, progression-free survival, event-free survival, and recurrence-free survival. |
Countries
China
Contacts
Primary ContactJian Chen, Ph.D
Outcome results
None listed